Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: November 4, 2003
Last updated: March 1, 2013
Last verified: March 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2006
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)